Cargando…
Randomized trial of nicotine replacement therapy (NRT), bupropion and NRT plus bupropion for smoking cessation: effectiveness in clinical practice
BACKGROUND AND AIMS: Bupropion was introduced for smoking cessation following a pivotal trial showing that it gave improved efficacy over the nicotine patch and also suggesting combination treatment was beneficial. We tested in clinical practice for an effectiveness difference between bupropion and...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4282128/ https://www.ncbi.nlm.nih.gov/pubmed/23859696 http://dx.doi.org/10.1111/add.12304 |
_version_ | 1782351078430343168 |
---|---|
author | Stapleton, John West, Robert Hajek, Peter Wheeler, Jenny Vangeli, Eleni Abdi, Zeinab O’Gara, Colin McRobbie, Hayden Humphrey, Kirsty Ali, Rachel Strang, John Sutherland, Gay |
author_facet | Stapleton, John West, Robert Hajek, Peter Wheeler, Jenny Vangeli, Eleni Abdi, Zeinab O’Gara, Colin McRobbie, Hayden Humphrey, Kirsty Ali, Rachel Strang, John Sutherland, Gay |
author_sort | Stapleton, John |
collection | PubMed |
description | BACKGROUND AND AIMS: Bupropion was introduced for smoking cessation following a pivotal trial showing that it gave improved efficacy over the nicotine patch and also suggesting combination treatment was beneficial. We tested in clinical practice for an effectiveness difference between bupropion and nicotine replacement therapy (NRT), whether the combination improves effectiveness and whether either treatment might be more beneficial for certain subgroups of smokers. DESIGN: Open-label randomized controlled trial with 6-month follow-up. SETTING: Four UK National Health Service (NHS) smoking cessation clinics. PARTICIPANTS: Smokers (n = 1071) received seven weekly behavioural support sessions and were randomized to an NRT product of their choice (n = 418), bupropion (n = 409) or NRT plus bupropion (n = 244). MEASURES: The primary outcome was self-reported cessation over 6 months, with biochemical verification at 1 and 6 months. Also measured were baseline demographics, health history, smoking characteristics and unwanted events during treatment. FINDINGS: Abstinence rates for bupropion (27.9%) and NRT (24.2%) were not significantly different (odds ratio = 1.21, 95% confidence interval = 0.883–1.67), and the combination rate (24.2%) was similar to that for either treatment alone. There was some evidence that the relative effectiveness of bupropion and NRT differed according to depression (χ(2) = 2.86, P = 0.091), with bupropion appearing more beneficial than NRT in those with a history of depression (29.8 versus 18.5%). Several unwanted symptoms were more common with bupropion. CONCLUSION: There is no difference in smoking cessation effectiveness among bupropion, nicotine replacement therapy and their combination when used with behavioural support in clinical practice. There is some evidence that bupropion is more beneficial than nicotine replacement therapy for smokers with a history of depression. |
format | Online Article Text |
id | pubmed-4282128 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BlackWell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-42821282015-01-15 Randomized trial of nicotine replacement therapy (NRT), bupropion and NRT plus bupropion for smoking cessation: effectiveness in clinical practice Stapleton, John West, Robert Hajek, Peter Wheeler, Jenny Vangeli, Eleni Abdi, Zeinab O’Gara, Colin McRobbie, Hayden Humphrey, Kirsty Ali, Rachel Strang, John Sutherland, Gay Addiction Research Reports BACKGROUND AND AIMS: Bupropion was introduced for smoking cessation following a pivotal trial showing that it gave improved efficacy over the nicotine patch and also suggesting combination treatment was beneficial. We tested in clinical practice for an effectiveness difference between bupropion and nicotine replacement therapy (NRT), whether the combination improves effectiveness and whether either treatment might be more beneficial for certain subgroups of smokers. DESIGN: Open-label randomized controlled trial with 6-month follow-up. SETTING: Four UK National Health Service (NHS) smoking cessation clinics. PARTICIPANTS: Smokers (n = 1071) received seven weekly behavioural support sessions and were randomized to an NRT product of their choice (n = 418), bupropion (n = 409) or NRT plus bupropion (n = 244). MEASURES: The primary outcome was self-reported cessation over 6 months, with biochemical verification at 1 and 6 months. Also measured were baseline demographics, health history, smoking characteristics and unwanted events during treatment. FINDINGS: Abstinence rates for bupropion (27.9%) and NRT (24.2%) were not significantly different (odds ratio = 1.21, 95% confidence interval = 0.883–1.67), and the combination rate (24.2%) was similar to that for either treatment alone. There was some evidence that the relative effectiveness of bupropion and NRT differed according to depression (χ(2) = 2.86, P = 0.091), with bupropion appearing more beneficial than NRT in those with a history of depression (29.8 versus 18.5%). Several unwanted symptoms were more common with bupropion. CONCLUSION: There is no difference in smoking cessation effectiveness among bupropion, nicotine replacement therapy and their combination when used with behavioural support in clinical practice. There is some evidence that bupropion is more beneficial than nicotine replacement therapy for smokers with a history of depression. BlackWell Publishing Ltd 2013-12 2013-08-28 /pmc/articles/PMC4282128/ /pubmed/23859696 http://dx.doi.org/10.1111/add.12304 Text en © 2013 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction http://creativecommons.org/licenses/by/3.0/ This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Reports Stapleton, John West, Robert Hajek, Peter Wheeler, Jenny Vangeli, Eleni Abdi, Zeinab O’Gara, Colin McRobbie, Hayden Humphrey, Kirsty Ali, Rachel Strang, John Sutherland, Gay Randomized trial of nicotine replacement therapy (NRT), bupropion and NRT plus bupropion for smoking cessation: effectiveness in clinical practice |
title | Randomized trial of nicotine replacement therapy (NRT), bupropion and NRT plus bupropion for smoking cessation: effectiveness in clinical practice |
title_full | Randomized trial of nicotine replacement therapy (NRT), bupropion and NRT plus bupropion for smoking cessation: effectiveness in clinical practice |
title_fullStr | Randomized trial of nicotine replacement therapy (NRT), bupropion and NRT plus bupropion for smoking cessation: effectiveness in clinical practice |
title_full_unstemmed | Randomized trial of nicotine replacement therapy (NRT), bupropion and NRT plus bupropion for smoking cessation: effectiveness in clinical practice |
title_short | Randomized trial of nicotine replacement therapy (NRT), bupropion and NRT plus bupropion for smoking cessation: effectiveness in clinical practice |
title_sort | randomized trial of nicotine replacement therapy (nrt), bupropion and nrt plus bupropion for smoking cessation: effectiveness in clinical practice |
topic | Research Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4282128/ https://www.ncbi.nlm.nih.gov/pubmed/23859696 http://dx.doi.org/10.1111/add.12304 |
work_keys_str_mv | AT stapletonjohn randomizedtrialofnicotinereplacementtherapynrtbupropionandnrtplusbupropionforsmokingcessationeffectivenessinclinicalpractice AT westrobert randomizedtrialofnicotinereplacementtherapynrtbupropionandnrtplusbupropionforsmokingcessationeffectivenessinclinicalpractice AT hajekpeter randomizedtrialofnicotinereplacementtherapynrtbupropionandnrtplusbupropionforsmokingcessationeffectivenessinclinicalpractice AT wheelerjenny randomizedtrialofnicotinereplacementtherapynrtbupropionandnrtplusbupropionforsmokingcessationeffectivenessinclinicalpractice AT vangelieleni randomizedtrialofnicotinereplacementtherapynrtbupropionandnrtplusbupropionforsmokingcessationeffectivenessinclinicalpractice AT abdizeinab randomizedtrialofnicotinereplacementtherapynrtbupropionandnrtplusbupropionforsmokingcessationeffectivenessinclinicalpractice AT ogaracolin randomizedtrialofnicotinereplacementtherapynrtbupropionandnrtplusbupropionforsmokingcessationeffectivenessinclinicalpractice AT mcrobbiehayden randomizedtrialofnicotinereplacementtherapynrtbupropionandnrtplusbupropionforsmokingcessationeffectivenessinclinicalpractice AT humphreykirsty randomizedtrialofnicotinereplacementtherapynrtbupropionandnrtplusbupropionforsmokingcessationeffectivenessinclinicalpractice AT alirachel randomizedtrialofnicotinereplacementtherapynrtbupropionandnrtplusbupropionforsmokingcessationeffectivenessinclinicalpractice AT strangjohn randomizedtrialofnicotinereplacementtherapynrtbupropionandnrtplusbupropionforsmokingcessationeffectivenessinclinicalpractice AT sutherlandgay randomizedtrialofnicotinereplacementtherapynrtbupropionandnrtplusbupropionforsmokingcessationeffectivenessinclinicalpractice |